# IVIG Treatment for Refractory Immune-Related Adult Epilepsy

> **NCT01545518** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 20 (actual)

## Conditions studied

- Epilepsy, Cryptogenic
- Epilepsy, Partial
- Seizure Disorder
- Autoimmune Diseases, Nervous System
- Limbic Encephalitis

## Interventions

- **DRUG:** IVIG

## Key facts

- **NCT ID:** NCT01545518
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-06
- **Final completion:** 2013-08
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Futility criteria, unable for Phase 2 of study, \& phase 1 was terminated.
- **Last updated:** 2014-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01545518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01545518, "IVIG Treatment for Refractory Immune-Related Adult Epilepsy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01545518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*